Tennessee is currently home to 1929 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04895241
Recruiting
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care medications. These may include antimalarials, steroids, and immunosuppressants. The main objective of the study is to learn about the effect litifilimab has on lowering the activity of the disease. The main question researchers want to answer is: -... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Ramesh C Gupta, MD, Memphis, Tennessee
Conditions: Lupus Erythematosus, Systemic
Register for Updates
Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT
NCT04678154
Recruiting
The proposed study is a multi-center, prospective randomized controlled trial comparing current standard of care treatment to the SEXTANT treatment protocol in patients with Type III open fractures of the tibia and IIIB fractures of the ankle and hindfoot.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
05/07/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Post Operative Surgical Site Infection
Register for Updates
Efficacy and Safety of VDPHL01 in Males With AGA
NCT06724614
Recruiting
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, mont... Read More
Gender:
MALE
Ages:
Between 18 years and 65 years
Trial Updated:
05/06/2025
Locations: Site 09, Knoxville, Tennessee
Conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness
Register for Updates
Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors
NCT06421987
Recruiting
SURVIVORS Study participants are being asked to take part in this research study called HODNIRS because the participant is a survivor of Hodgkin Lymphoma (HL) treated with chest radiation and bleomycin at St. Jude Children's Research Hospital. The study is being done to help investigators understand the link between long term effects of chest radiation and bleomycin for HL and brain function in survivors. Primary Objective To evaluate dynamic changes in CBF and oxygenation during exercise with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Hodgkin Lymphoma, Adult
Register for Updates
School Readiness Intervention for Preschool Children With Sickle Cell Disease
NCT06367192
Recruiting
The study participant is being asked to take part in this clinical trial, a type of research study, because the participant is a young child with sickle cell disease or the caregiver of a child with sickle cell disease. This study is being done to test a school readiness program for children with sickle cell disease (ages 3.5-6,5 years old). Primary Objective Assess feasibility and acceptability of an adapted school readiness intervention among preschool children (ages 3.5-6.5) diagnosed with... Read More
Gender:
ALL
Ages:
Between 42 months and 78 months
Trial Updated:
05/06/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Sickle Cell Disease
Register for Updates
Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)
NCT06152237
Recruiting
The REVEAL Pediatric Study is a multi-center, Phase 1/2 open-label, dose-escalation and dose-expansion study of TSHA-102, an investigational gene therapy, in pediatric females with Rett Syndrome. The safety, tolerability, and preliminary efficacy of two dose levels will be evaluated. The study duration is up to 6 years.
Gender:
FEMALE
Ages:
Between 5 years and 8 years
Trial Updated:
05/06/2025
Locations: Vanderbilt Kennedy Center, Nashville, Tennessee
Conditions: Rett Syndrome
Register for Updates
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
NCT06100874
Recruiting
This research study is being done to evaluate the safety and effectiveness of sacituzumab govitecan with trastuzumab (Herceptin, Herceptin Hylecta, or trastuzumab biosimilar) in metastatic HER2+ breast cancer. The names of the study drugs used in this research study are: * Sacituzumab govitecan (a type of antibody-drug conjugate) * Trastuzumab (Herceptin) (a type of monoclonal antibody) * Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta) (a type of recombinant monoclonal antibody) * Trast... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: SCRI Oncology Partners, Nashville, Tennessee
Conditions: Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic
Register for Updates
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
NCT05831111
Recruiting
The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/06/2025
Locations: Alliance for Multispecialty Research, LLC, Knoxville, Tennessee
Conditions: Epstein-Barr Virus Infection
Register for Updates
COgnitive and Physical Exercise to Improve Outcomes After Surgery (COPE-iOS) Study
NCT04889417
Recruiting
The COgnitive and Physical Exercise to improve Outcomes after Surgery (COPE-iOS) study is testing the hypothesis that a pragmatic program combining computerized cognitive training and physical training throughout the perioperative period will improve long-term cognitive and disability outcomes in older surgical patients at high risk for decline. To accomplish these goals, the Investigators are randomizing 250 patients ≥60 years old undergoing elective major non-cardiac surgery with expected hosp... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
05/06/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Cognitive Impairment, Disability Physical, Surgery
Register for Updates
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
NCT04781140
Recruiting
This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.
Gender:
ALL
Ages:
Between 48 months and 69 months
Trial Updated:
05/06/2025
Locations: Clinical Neuroscience Solutions, Inc., Memphis, Tennessee
Conditions: Attention-Deficit/Hyperactivity Disorder
Register for Updates
Project Talk Trial: Engaging Underserved Communities in End-of-life Conversations
NCT04612738
Recruiting
Compared to the general population, individuals from underserved communities are more likely to receive low quality end-of-life care and unwanted, costly and burdensome treatments due in part to a lack of advance care planning (ACP; the process of discussing wishes for end-of-life care with loved ones/clinicians and documenting them in advance directives). This study will use existing, trusted, and respected social networks to evaluate two conversation-based tools intended to engage underserved... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Welcome Home of Chattanooga, Chattanooga, Tennessee
Conditions: Advance Care Planning, Advance Directives, Terminal Illness, Chronic Illness, Communication
Register for Updates
Volatility in Paranoia (VIP) Trial: An RCT of Changes in Volatility With Psychotherapy
NCT06835556
Recruiting
The goal of this clinical trial is to learn whether learning and belief updating change in response to the treatment of persecutory delusions, in individuals with schizophrenia-spectrum disorders. The main questions are: 1. do prior expectations about environmental volatility reduce following effective psychotherapeutic treatment of delusions? 2. does corresponding brain activity related to volatility change with effective treatment of delusions? Participants will: 1. engage in CBTp or TAU +... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/05/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Schizophrenia Disorders
Register for Updates